Abstract | PURPOSE: METHODS: A file review was performed for all consecutive patients with newly diagnosed exudative age-related macular degeneration and initial VA of ≥ 20/40 treated in 2005 to 2010 and followed for at least 6 months. Treatment consisted of 3 loading doses of intravitreal bevacizumab every 6 weeks and was repeated when fluid or hemorrhage was present. RESULTS: The cohort included 130 patients (150 eyes). Mean follow-up was 20.2 ± 13.2 months, and mean number of injections was 11.3 ± 6.2. At the last examination, VA was stable or improved in 106 eyes (70.7%); 11 eyes (7.3%) lost ≥ 3 lines. Mean logarithm of the minimum angle of resolution VA measured 0.22 ± 0.1 (0-0.3) at presentation and 0.22 ± 0.2 (0-1.3) at the last visit. Corresponding values for central macular thickness were 267 ± 75 μm (137-562) and 226 ± 75 μm (75-568) (P = 0.14). The most frequent complication (18 eyes, 12%) was corneal epithelial defects. CONCLUSION: Prompt intravitreal bevacizumab treatment for newly diagnosed exudative age-related macular degeneration in patients with good initial best-corrected visual acuity is associated with sustained or improved vision and a good safety profile. Attempts should be made to expedite the access of these patients to treatment, regardless of initial VA.
|
Authors | Ruth Axer-Siegel, Elite Bor, Dan H Bourla, Dov Weinberger, Karin Mimouni |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 32
Issue 9
Pg. 1811-20
(Oct 2012)
ISSN: 1539-2864 [Electronic] United States |
PMID | 22825407
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects)
- Bevacizumab
- Exudates and Transudates
- Female
- Follow-Up Studies
- Humans
- Intraocular Pressure
(drug effects)
- Intravitreal Injections
- Male
- Middle Aged
- Retina
(pathology)
- Retreatment
- Retrospective Studies
- Tonometry, Ocular
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Wet Macular Degeneration
(drug therapy, physiopathology)
|